UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,431	09/15/2003	David W. Morris	PP023357.0001 2348 /20366-0710	
Lisa E. Alexand	7590 07/29/200 <sup>.</sup> <b>ler</b>	EXAMINER		
Sagres Discover		YAO, LEI		
c/o Chiron Corporation P.O. Box 8097			ART UNIT	PAPER NUMBER
Emeryville, CA	94662-8097	1642		
			MAIL DATE	DELIVERY MODE
			07/29/2009	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/663,431	MORRIS ET AL.		
Examiner	Art Unit		
LEI YAO	1642		

	LEI YAO	1642					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress				
THE REPLY FILED 13 July 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1.  The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request				
a) The period for reply expires <u>6</u> months from the mailing date	of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Adno event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	dvisory Action, or (2) the date set forth in ter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.				
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL							
<ol> <li>The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi</li> </ol>	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
AMENDMENTS		20 (					
3. The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further cor (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bett	nsideration and/or search (see NOT w);	E below);					
appeal; and/or (d) ☐ They present additional claims without canceling a c	.,,						
NOTE: (See 37 CFR 1.116 and 41.33(a)).							
4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s):		mpliant Amendment (I	PTOL-324).				
<ol> <li>Applicant's reply has overcome the lonowing rejection(s).</li> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>		imely filed amendmer	nt canceling the				
<ul> <li>7.  For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:</li> </ul>		be entered and an ex	xplanation of				
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 74,76-78,90,93,94. Claim(s) withdrawn consideration:							
AFFIDAVIT OR OTHER EVIDENCE	hefere or on the date of filing a Ne	tice of Annaal will not	he entered				
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>							
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fails	s to provide a				
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	itry is below or attach	ed.				
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet.</u>							
<ul><li>12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (</li><li>13. ☐ Other:</li></ul>	PTO/SB/08) Paper No(s)						
/Larry R. Helms/	/Lei Yao, Ph.D./						
Supervisory Patent Examiner, Art Unit 1643	Examiner, Art Unit 1642						

Continuation of 11. does NOT place the application in condition for allowance because: Applicant respond the Final Office action with argument without amending the claims, which is acknowledged and entered. The arguments have been considered, but not found persuasive to overcome the rejection. For example, in 102 rejection, Applicant argues that the tissue samepls in Martensen's reference are all preselected because they are breast carcinoma, there is no disclosure of an active step of diagnosing cancer based on 50% increased in the exporession product (page 8). In response, step of "daignosing cancer" is NOT considered as an active step of instantly claimed method, it is a mental step. The claims recited comparing a level so VLDLR in the breast cancer tissues to the normal control. Matensen et al disclose the same method step of determining the levels of the same material, VLDLR, from the same population of the patients, breast cancer patients. In addition, the instant claim 74 recites an increase of at least 50% of the VLDLR mRNA relative to the levels of the normal control for diagnosing breast cancer. The reference teaches more than 50% or 100% increase of VLDLR in the breast cancer patients. Thus, Applicant's argument is not pursuasive and rejection is maintained currently.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lei Yao, Ph.D. whose telephone number is 571-272-3112. The examiner can normally be reached on 8am-6.00pm Monday-Thursday.

Any inquiry of a general nature, matching or file papers or relating to the status of this application or proceeding should be directed to Kim Downing for Art Unit 1642 whose telephone number is 571-272-0521

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

LY